P. Fabris

发表

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

T. Barbui, A. Bosi, A. Gallamini, 2009, Blood.

Poster Sessions I and II , Interdisciplinary Workshop, Satelite Symposia I-IV

T. Chisesi, A. Rambaldi, R. Bassan, 2004, Annals of Hematology.

Role of anthracycline dose intensity in adult Philadelphia chromosome/BCR-ABL positive and negative B-lineage acute lymphoblastic leukemia

T. Lister, A. Rohatiner, T. Barbui, 1999 .

Early Application of Anthracyclines in Adult Acute Lymphoblastic Leukemia (ALL)

T. Lister, A. Rohatiner, T. Barbui, 2001 .

Impact of interferon at induction chemotherapy and maintenance treatment for multiple myeloma. Preliminary results of a multicenter study by the Italian non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG).

V. Rizzoli, A. Contu, G. Capnist, 1994, Acta oncologica.

Preliminary Results of a Risk-Oriented Program for B-Lineage Adult Acute Lymphoblastic Leukemia (ALL): The Collaborative Italian Study 08/96

T. Barbui, G. Rossi, P. Casula, 2001 .

Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.

T. Barbui, G. Rossi, E. Angelucci, 2007, Haematologica.

Prognostic Factors in Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia

T. Lister, A. Rohatiner, T. Barbui, 2001 .

The role of anthracyclines in adult acute lymphoblastic leukaemia.

T. Barbui, A. Rambaldi, R. Bassan, 1996, Leukemia.

Limited Success with a Postremission Strategy Comprising Conventional Consolidation and High-Dose Treatment (HDT) with Autologous Peripheral Progenitor Cell (PBPC) Support for Adult Acute Lymphoblastic Leukaemia (ALL)

T. Lister, A. Rohatiner, T. Barbui, 2003 .

Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.

T. Barbui, G. Rossi, P. Casula, 1999, Haematologica.

Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups.

T. Barbui, G. Rossi, A. Cortelezzi, 2001, The hematology journal : the official journal of the European Haematology Association.

Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.

T. Lister, A. Rohatiner, T. Barbui, 2000, The hematology journal : the official journal of the European Haematology Association.

Clinical sensitivity to anthracyclines in PH/BCR+ acute lymphoblastic leukemia.

T. Lister, A. Rohatiner, T. Barbui, 1999, Advances in experimental medicine and biology.

Possible Prognostic Benefit from ABMT in First Remission Adult Acute Lymphoblastic Leukemia

T. Barbui, A. Rambaldi, R. Bassan, 2000 .

Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL).

T. Chisesi, M. Federico, T. Lamparelli, 1994, Leukemia & lymphoma.

Lymphoblastic Leukemia (all) Molecular Study of Minimal Residual Disease (mrd) in Adult Acute Improved Risk Classification for Risk-specific Therapy Based on The

T. Barbui, A. Bosi, A. Gallamini, 2009 .

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

T. Barbui, A. Bosi, A. Gallamini, 2009 .

"Isolated" peritoneal granulocytic sarcoma with molecular and chromosomal bone marrow involvement.

P. Fabris, A. Billio, Graziano Pianezze, 2002, Haematologica.